Bioporto A/S
CSE:BIOPOR
Bioporto A/S
CSE:BIOPOR
Price:
1.628 DKK
11.35%
Market Closed
Updated:
May 12, 2024
Section:
Relative Value
The Relative Value of one
BIOPOR
stock under the Base Case scenario is
1.47
DKK.
Compared to the current market price of 1.628 DKK,
Bioporto A/S
is
Overvalued by 10%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BIOPOR
Relative Value
Base Case
1.47
DKK
Overvaluation 10%
Valuation Multiples
Multiples Across Competitors
BIOPOR Competitors Multiples
Bioporto A/S Competitors
Bioporto A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Bioporto A/S
CSE:BIOPOR
|
618.1m DKK | 20 | -11 | -9.7 | -9.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | 44.2 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | 30.1 | 24.2 | 25.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | 27.8 | 22.5 | 24.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.9B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 169.8 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | -7.5 | -8.1 | -7.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.6 | 45.6 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
